口服cyclophosphamide治療復發性卵巢癌的檢視

10.6666/ClinMed.2017.80.6.134

李耀泰；陳福民；郭宗正

節拍器式口服cyclophosphamide(metronomic oral cyclophosphamide) ； bevacizumab ； 復發性卵巢癌(recurrent ovarian cancer)

臨床醫學月刊

80卷6期（2017 / 12 / 29）

741 - 745

繁體中文

上皮性卵巢癌患者發現時多為晚期，化學治療的效果雖好，然復發率仍高。一旦復發，須再次進行手術、局部電療或化學治療。但在多次化學治療無效者，會出現許多副作用，因此有尋求有效、副作用少的化療方法。最近研究認為，對多次化學治療的復發性卵巢癌患者，每天予以口服低劑量cyclophosphamide(或合併bevacizumab)來阻斷血管生長。因療效不差，值得繼續深入研究。

1. Barber, EL,Zsiros, E,Lurain, JR(2013).The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer.J Gynecol Oncol,24,258-264.
2. Chura, JC,Iseghem, KV,Downs, LS., Jr.(2007).Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.Gynecol Oncol,107,326-330.
3. El-Husseiny, K,Motawei, H,Ali, MS(2016).Continuous low-dose oral cyclophosphamide and methotrexate as maintenance therapy in patients with advanced ovarian carcinoma after complete clinical response to platinum and paclitaxel chemotherapy.Int J Gynecol Cancer,26,437-442.
4. Ferrandina, G,Corrado, G,Mascilini, F(2014).Metronomic oral cyclophosphamide(MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study.BMC Cancer,14,947.
5. Garcia, AA,Hiorte, H,Fleming, G(2008).Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.J Clin Oncol,26,76-82.
6. Handolias, D,Quinn, M,Foo, S(2016).Oral cyclophosphamide in recurrent ovarian cancer.Asia Pac J Clin Oncol,12,e154-e160.
7. Matulonis, U,Pereira, L,Liu, J(2012).Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer.Gynecol Oncol,126,41-46.
8. Penel, N,Adenis, A,Bocci, G(2012).Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?.Crit Rev Oncol Hematol,82,40-50.
9. Perroud, HA,Scharovsky, OG,Rozados, VR(2017).Clinical response in patients with ovarian cancer treated with metronomic chemotherapy.Cancer,11,723.
10. Samaritani, R,Corrado, G,Vizza, E(2007).Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.BMC Cancer,7,65.
11. Sanchez Munoz, A,Mendiola, C,Perez-Ruiz, E(2010).Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.Oncology,79,98-104.
12. Su, WH,Ho, TY,Li, YT(2012).Metronomic therapy for gynecologic cancers.Taiwan J Obstet Gynecol,51,167-178.
13. Watanabe, Y,Etoh, T,Koike, E(2010).Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer.Int J Clin Oncol,15,468-471.
14. Wong, CN,Wong, CN,Liu, FS(2017).Continuous oral cyclophosphamide as salvage or maintenance therapy in ovarian, primary peritoneal, and fallopian tube cancers: a retrospective, single institute study.Taiwan J Obstet Gynecol,56,302-305.